| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
As an N-substituted hydroxylamine, N-benzylhydroxylamine hydrochloride does not have specific biological receptors as its primary targets. The compound is primarily used as a synthetic intermediate in nitrone chemistry and pharmaceutical synthesis. The compound has been identified as a potential pharmacological agent in the prevention and progression of acrolein-induced damage to the retinal pigment epithelium. Its mechanism of action in this context may involve scavenging of reactive aldehydes or modulation of oxidative stress pathways. The compound's hydroxylamine functionality allows it to participate in various chemical transformations, including oxidation to nitrones and condensation reactions.
|
|---|---|
| ln Vitro |
One possible pharmacological intervention for acrolein-induced retinal pigment epithelial cell damage is the use of N-benzylhydroxylamine.
In vitro, N-benzylhydroxylamine hydrochloride is used as a biochemical reagent and synthetic intermediate. It is broadly utilized in nitrone chemistry, 1,3-dipolar cycloadditions, and pharmaceutical synthesis. It may be used in the preparation of a precursor to aminocyclopentitol derivatives. Cellular assays are typically performed on the final compounds synthesized from this intermediate. The compound has been identified as a potential pharmacological agent for preventing acrolein-induced damage to the retinal pigment epithelium. Cellular assays may evaluate its protective effects against oxidative stress or aldehyde-induced damage. |
| ln Vivo |
In vivo data for N-benzylhydroxylamine hydrochloride is limited, as it is primarily a research reagent and synthetic intermediate. The compound is classified for research use only and is not intended for human or veterinary therapeutic applications. The compound has been identified as a potential pharmacological agent in the prevention and progression of acrolein-induced damage to the retinal pigment epithelium, suggesting potential for ophthalmic applications. Specific in vivo data for therapeutic applications is not available in the public literature. The compound's primary value lies in its use as a synthetic intermediate.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for N-benzylhydroxylamine hydrochloride are not typically performed, as it is primarily a synthetic intermediate. The compound is used as a building block in organic synthesis, including nitrone chemistry and 1,3-dipolar cycloadditions. A typical assay involves using the compound in chemical reactions to prepare final compounds. The compound is dissolved in organic solvents such as ethanol or DMSO. The resulting products can be evaluated for biological activity. Enzyme inhibition or receptor binding assays can be performed on the final synthesized compounds. IC₅₀ or binding affinity values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for N-benzylhydroxylamine hydrochloride may evaluate its protective effects against oxidative stress or aldehyde-induced damage. A standard protocol involves culturing retinal pigment epithelial cells in growth medium at 37°C with 5% CO₂. Cells are treated with acrolein to induce damage and with varying concentrations of the compound. Cell viability is assessed using MTT or similar assays. Oxidative stress markers such as reactive oxygen species, lipid peroxidation, and antioxidant enzyme activity are measured. The compound's protective effects are evaluated by comparing damage in treated vs. untreated cells. IC₅₀ values are calculated from dose-response curves.
|
| Animal Protocol |
In vivo animal studies for N-benzylhydroxylamine hydrochloride are not standard, as it is primarily a research reagent. The compound is classified for research use only and is not intended for human or veterinary applications. Any animal studies would be limited to evaluating its potential as a protective agent against retinal damage. The compound's primary value lies in its use as a synthetic intermediate. Specific in vivo protocols are not available in the public literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for N-benzylhydroxylamine hydrochloride is limited, as it is primarily a research reagent. The compound has a molecular weight of 159.61 g/mol and a molecular formula of C₇H₁₀ClNO. It is a solid at room temperature. As a hydroxylamine, it may undergo oxidation and conjugation in biological systems. The compound is soluble in water and organic solvents. Specific ADME data is not available. The compound is stored in a dry, cool place.
|
| Toxicity/Toxicokinetics |
N-Benzylhydroxylamine hydrochloride is classified for research use only and is not intended for human or veterinary applications. Standard safety precautions include handling with appropriate personal protective equipment (gloves, lab coat, safety goggles) in a well-ventilated area. The compound should be stored in a dry, cool place away from incompatible materials. Acute toxicity data is not readily available in the public literature. As with all research chemicals, appropriate laboratory safety practices should be followed. No specific LD₅₀ values or detailed toxicological profiles are available in the public domain.
|
| Additional Infomation |
N-Benzylhydroxylamine hydrochloride (CAS 29601-98-7) is a biochemical reagent with the molecular formula C₇H₁₀ClNO. It is an N-substituted hydroxylamine salt used as a synthetic intermediate in nitrone chemistry, 1,3-dipolar cycloadditions, and pharmaceutical synthesis. The compound is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes. It is available from multiple commercial suppliers in various pack sizes. No clinical trials or approved drug status exist for this compound as it is not a therapeutic agent. Its applications are limited to research and chemical synthesis.
|
| Molecular Formula |
C7H10CLNO
|
|---|---|
| Molecular Weight |
159.61
|
| Exact Mass |
159.045
|
| CAS # |
29601-98-7
|
| PubChem CID |
11332622
|
| Appearance |
White to light yellow solid powder
|
| Boiling Point |
253.9ºC at 760 mmHg
|
| Melting Point |
108-110ºC
|
| Flash Point |
135.2ºC
|
| LogP |
2.358
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
10
|
| Complexity |
69.3
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ONCC1=CC=CC=C1.[H]Cl
|
| InChi Key |
YSNXOQGDHGUKCZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H9NO.ClH/c9-8-6-7-4-2-1-3-5-7;/h1-5,8-9H,6H2;1H
|
| Chemical Name |
N-benzylhydroxylamine;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.2653 mL | 31.3264 mL | 62.6527 mL | |
| 5 mM | 1.2531 mL | 6.2653 mL | 12.5305 mL | |
| 10 mM | 0.6265 mL | 3.1326 mL | 6.2653 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
